Monopar Therapeutics (NASDAQ:MNPR) Trading Down 8.9% – Should You Sell?

Monopar Therapeutics Inc. (NASDAQ:MNPR)’s stock price dropped 8.9% on Thursday . The company traded as low as $101.00 and last traded at $102.4440. 39,515 shares traded hands during trading, a decline of 81% from the average daily volume of 210,904 shares. The stock had previously closed at $112.48.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on MNPR shares. Chardan Capital restated a “buy” rating and issued a $100.00 target price on shares of Monopar Therapeutics in a report on Monday, March 30th. Wall Street Zen lowered shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, July 12th. BTIG Research increased their price target on shares of Monopar Therapeutics from $104.00 to $117.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, July 15th. Finally, Piper Sandler set a $105.00 price target on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. Three analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $112.08.

Monopar Therapeutics Stock Performance

The stock has a market capitalization of $694.42 million, a P/E ratio of -54.55 and a beta of 1.46. The stock has a 50-day moving average price of $78.59 and a two-hundred day moving average price of $66.08.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.41. Equities analysts anticipate that Monopar Therapeutics Inc. will post -2.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in MNPR. Bank of America Corp DE raised its holdings in Monopar Therapeutics by 838.2% in the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after purchasing an additional 53,336 shares in the last quarter. ADAR1 Capital Management LLC boosted its stake in shares of Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after purchasing an additional 30,370 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Monopar Therapeutics during the 1st quarter valued at about $250,000. Siren L.L.C. increased its position in shares of Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after buying an additional 57,820 shares during the period. Finally, Sei Investments Co. increased its position in shares of Monopar Therapeutics by 9.5% during the first quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock valued at $415,000 after buying an additional 656 shares during the period. 1.83% of the stock is owned by hedge funds and other institutional investors.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.